Last reviewed · How we verify
NCT00781573: SCORE
Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)
NA trial testing Clopidogrel in Myocardial Infarction in 167 participants. Completed in 3 March 2014.
3 March 2014
Quick facts
| Lead sponsor | North Texas Veterans Healthcare System |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 167 |
| Start date | 11 September 2008 |
| Primary completion | 3 March 2014 |
| Estimated completion | 3 March 2014 |
| Sites | 3 locations across United States, Greece, India |
Drugs / interventions tested
- Clopidogrel (clopidogrel) — full drug profile →
Conditions studied
- Myocardial Infarction — all drugs for Myocardial Infarction →
Sponsor
North Texas Veterans Healthcare System
Who can join
21 and older, any sex, with Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Although the optimal duration of clopidogrel (an anti-platelet agent) therapy has been established after bare metal stent implantation in the blood vessels of the heart, there is lack of consensus regarding the optimal duration of therapy after implantation of a drug eluting stents (DES). Current American College of Cardiology guidelines recommend clopidogrel use for at least one year in the absence of contraindications after DES implantation, while recognizing that the optimal duration remains unknown. While an extended clopidogrel therapy (that is beyond the current 1 year recommendation) may increase bleeding complication, it may reduce the rates of adverse cardiovascular events like heart attacks and repeat revascularization procedures. A clinical trial which randomizes patients with an uneventful one year course after a DES implantation, to an additional year of clopidogrel and aspirin therapy versus aspirin alone, will be able to answer the important question about the role of extended (2y) dual anti-platelet therapy with clopidogrel and aspirin after DES implants. The investigators hypothesize that clopidogrel discontinuation at 1 year post-DES implantation is associated with an increase in cardiovascular events during the one year of follow-up period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00781573
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Clopidogrel
Trials testing the same drug.
- NCT07012629 — A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in P · Phase 3 · recruiting
- NCT07025148 — Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding · Phase 4 · recruiting
- NCT07180472 — Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol · Phase 4 · not yet recruiting
- NCT06757764 — The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis · Phase 4 · recruiting
- NCT07040787 — Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects · Phase 1 · completed
Other recruiting trials for Myocardial Infarction
Currently open trials in the same condition.
- NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
- NCT07402642 — Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome · NA · recruiting
- NCT07301034 — A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, · Phase 3 · recruiting
- NCT07142265 — Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients · recruiting
- NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting
Other North Texas Veterans Healthcare System trials
Trials by the same sponsor.
- NCT03150667 — Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD · Phase 4 · unknown
- NCT03929939 — Neural Control and Cardiac-Vascular Function in Women With PTSD (VA Psychological Assessment) · NA · completed
- NCT02387658 — Outcomes in Femoropopliteal Disease Stratified by Translesional Pressure Gradient · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00781573 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by North Texas Veterans Healthcare System
- Last refreshed: 13 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00781573.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing